{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:18:53Z","timestamp":1772165933980,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Peter Mac Foundation"},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Understanding the drivers of recurrence in aggressive prostate cancer requires detailed molecular and genomic understanding in order to aid therapeutic interventions.\nWe provide here a case report of histological, transcriptional, proteomic, immunological, and genomic features in a longitudinal study of multiple biopsies from diagnosis, through treatment, and subsequent recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Here we present a case study of a male in 70\u00a0s with high-grade clinically-localised acinar adenocarcinoma treated with definitive hormone therapy and radiotherapy. The patient progressed rapidly with rising PSA and succumbed without metastasis 52\u00a0months after diagnosis.\nWe identified the expression of canonical histological markers of neuroendocrine PC (NEPC) including synaptophysin, neuron-specific enolase and thyroid transcription factor 1, as well as intact AR expression, in the recurrent disease only.\nThe resistant disease was also marked by an extremely low immune infiltrate, extensive genomic chromosomal aberrations, and overactivity in molecular hallmarks of NEPC disease including Aurora kinase and E2F, as well as novel alterations in the cMYB pathway. We also observed that responses to both primary treatments (high dose-rate brachytherapy and androgen deprivation therapies) were consistent with known optimal responses\u2014ruling out treatment inefficacy as a factor in relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data provide novel insights into a case of locally recurrent aggressive prostate cancer harbouring NEPC pathology, in the absence of detected metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-020-00738-8","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T08:02:42Z","timestamp":1603872162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Scott G.","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Xian","family":"Aw Yeang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Caramia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf B.","family":"Schittenhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Neeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ygal","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-9138","authenticated-orcid":false,"given":"Simon P.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"issue":"2","key":"738_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-017-0568-7","volume":"19","author":"M Nakazawa","year":"2017","unstructured":"Nakazawa M, Paller C, Kyprianou N. Mechanisms of therapeutic resistance in prostate cancer. Curr Oncol Rep. 2017;19(2):13.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"738_CR2","doi-asserted-by":"publisher","first-page":"e000792","DOI":"10.1136\/jitc-2020-000792","volume":"8","author":"SP Keam","year":"2020","unstructured":"Keam SP, et al. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. J Immunother Cancer. 2020;8(1):e000792.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"738_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/pros.23500","volume":"78","author":"SP Keam","year":"2018","unstructured":"Keam SP, et al. Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry. Prostate. 2018a;78(8):563\u201375.","journal-title":"Prostate"},{"issue":"1","key":"738_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.09.037","volume":"100","author":"SP Keam","year":"2018","unstructured":"Keam SP, et al. The transcriptional landscape of radiation-treated human prostate cancer: analysis of a prospective tissue cohort. Int J Radiat Oncol Biol Phys. 2018b;100(1):188\u201398.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"738_CR5","doi-asserted-by":"publisher","first-page":"7072","DOI":"10.1158\/1078-0432.CCR-17-0413","volume":"23","author":"DP Labbe","year":"2017","unstructured":"Labbe DP, et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res. 2017;23(22):7072\u201383.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"738_CR6","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.7150\/jca.23681","volume":"9","author":"L Ren","year":"2018","unstructured":"Ren L, et al. Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis. J Cancer. 2018;9(12):2082\u201392.","journal-title":"J Cancer"},{"issue":"8","key":"738_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/00365520903039952","volume":"44","author":"A Hille","year":"2009","unstructured":"Hille A, et al. Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: results of a prospective study. Scand J Gastroenterol. 2009;44(8):939\u201346.","journal-title":"Scand J Gastroenterol"},{"key":"738_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1476-4598-6-39","volume":"6","author":"U Jariwala","year":"2007","unstructured":"Jariwala U, et al. Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer. 2007;6:39.","journal-title":"Mol Cancer"},{"issue":"1","key":"738_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00432-015-1992-4","volume":"142","author":"CV Vaz","year":"2016","unstructured":"Vaz CV, et al. Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes. J Cancer Res Clin Oncol. 2016;142(1):5\u201316.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"738_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/modpathol.2013.127","volume":"27","author":"K Grupp","year":"2014","unstructured":"Grupp K, et al. High nuclear karyopherin alpha 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Mod Pathol. 2014;27(1):96\u2013106.","journal-title":"Mod Pathol"},{"issue":"5","key":"738_CR11","doi-asserted-by":"publisher","first-page":"e37225","DOI":"10.1371\/journal.pone.0037225","volume":"7","author":"X Qian","year":"2012","unstructured":"Qian X, et al. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker. PLoS ONE. 2012;7(5):e37225.","journal-title":"PLoS ONE"},{"issue":"6","key":"738_CR12","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.juro.2013.05.004","volume":"190","author":"G Lucarelli","year":"2013","unstructured":"Lucarelli G, et al. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. J Urol. 2013;190(6):2271\u20137.","journal-title":"J Urol"},{"key":"738_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1186\/1471-2407-10-680","volume":"10","author":"EL Maresh","year":"2010","unstructured":"Maresh EL, et al. Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer. 2010;10:680.","journal-title":"BMC Cancer"},{"issue":"4","key":"738_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00428-013-1390-8","volume":"462","author":"M Montani","year":"2013","unstructured":"Montani M, et al. Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. Virchows Arch. 2013;462(4):437\u201343.","journal-title":"Virchows Arch"},{"issue":"6","key":"738_CR15","first-page":"1541","volume":"36","author":"Y Feng","year":"2010","unstructured":"Feng Y, et al. Downregulation of 15-lipoxygenase 2 by glucocorticoid receptor in prostate cancer cells. Int J Oncol. 2010;36(6):1541\u20139.","journal-title":"Int J Oncol"},{"issue":"18","key":"738_CR16","doi-asserted-by":"publisher","first-page":"16189","DOI":"10.1074\/jbc.M111936200","volume":"277","author":"S Tang","year":"2002","unstructured":"Tang S, et al. Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem. 2002;277(18):16189\u2013201.","journal-title":"J Biol Chem"},{"issue":"3","key":"738_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/jmcb\/mjq001","volume":"2","author":"MI Hassan","year":"2010","unstructured":"Hassan MI, Toor A, Ahmad F. Progastriscin: structure, function, and its role in tumor progression. J Mol Cell Biol. 2010;2(3):118\u201327.","journal-title":"J Mol Cell Biol"},{"issue":"5","key":"738_CR18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.2353\/ajpath.2010.090737","volume":"176","author":"S Breuninger","year":"2010","unstructured":"Breuninger S, et al. Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression. Am J Pathol. 2010;176(5):2509\u201319.","journal-title":"Am J Pathol"},{"issue":"3","key":"738_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298\u2013305.","journal-title":"Nat Med"},{"issue":"4","key":"738_CR20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","volume":"20","author":"HL Tan","year":"2014","unstructured":"Tan HL, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20(4):890\u2013903.","journal-title":"Clin Cancer Res"},{"issue":"6320","key":"738_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78\u201383.","journal-title":"Science"},{"issue":"6","key":"738_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487\u201395.","journal-title":"Cancer Discov"},{"issue":"11\u201312","key":"738_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.18632\/oncoscience.462","volume":"5","author":"TC Thompson","year":"2018","unstructured":"Thompson TC, Liu B, Li L. N-MYC regulation of DNA damage response in neuroendocrine prostate cancer: mechanistic insight and novel combination therapy approaches. Oncoscience. 2018;5(11\u201312):273\u20135.","journal-title":"Oncoscience"},{"issue":"29","key":"738_CR24","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1038\/onc.2014.308","volume":"34","author":"Z Mounir","year":"2015","unstructured":"Mounir Z, et al. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 2015;34(29):3815\u201325.","journal-title":"Oncogene"},{"issue":"47","key":"738_CR25","doi-asserted-by":"publisher","first-page":"E6544","DOI":"10.1073\/pnas.1518007112","volume":"112","author":"BA Smith","year":"2015","unstructured":"Smith BA, et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proc Natl Acad Sci U S A. 2015;112(47):E6544\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"738_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12943-019-0941-2","volume":"18","author":"Y Yin","year":"2019","unstructured":"Yin Y, et al. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421\/ATM pathway. Mol Cancer. 2019;18(1):11.","journal-title":"Mol Cancer"},{"issue":"15","key":"738_CR27","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/pros.23425","volume":"77","author":"M Kanayama","year":"2017","unstructured":"Kanayama M, et al. Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1. Prostate. 2017;77(15):1489\u201398.","journal-title":"Prostate"},{"key":"738_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41420-019-0218-y","volume":"5","author":"J Shan","year":"2019","unstructured":"Shan J, et al. Targeting Wnt\/EZH2\/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer. Cell Death Discov. 2019;5:139.","journal-title":"Cell Death Discov"},{"issue":"6","key":"738_CR29","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.celrep.2015.07.012","volume":"12","author":"S Akamatsu","year":"2015","unstructured":"Akamatsu S, et al. The placental gene PEG10 promotes progression of neuroendocrine prostate Cancer. Cell Rep. 2015;12(6):922\u201336.","journal-title":"Cell Rep"},{"issue":"1","key":"738_CR30","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1186\/s12885-017-3729-z","volume":"17","author":"HK Tsai","year":"2017","unstructured":"Tsai HK, et al. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer. 2017;17(1):759.","journal-title":"BMC Cancer"},{"issue":"6","key":"738_CR31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/carcin\/bgs134","volume":"33","author":"SK Srivastava","year":"2012","unstructured":"Srivastava SK, et al. Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis. 2012;33(6):1149\u201357.","journal-title":"Carcinogenesis"},{"issue":"1","key":"738_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/1078-0432.CCR-09-1423","volume":"16","author":"AT El Gammal","year":"2010","unstructured":"El Gammal AT, et al. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res. 2010;16(1):56\u201364.","journal-title":"Clin Cancer Res"},{"key":"738_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-015-0204-7","volume":"8","author":"KC Kadakia","year":"2015","unstructured":"Kadakia KC, et al. Comprehensive serial molecular profiling of an \u201cN of 1\u201d exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. J Hematol Oncol. 2015;8:109.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"738_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/JME-18-0226","volume":"63","author":"S Kim","year":"2019","unstructured":"Kim S, et al. PEG10 is associated with treatment-induced neuroendocrine prostate cancer. J Mol Endocrinol. 2019;63(1):39\u201349.","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"738_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00411-018-0746-5","volume":"57","author":"SP Keam","year":"2018","unstructured":"Keam SP, et al. Biodosimetric transcriptional and proteomic changes are conserved in irradiated human tissue. Radiat Environ Biophys. 2018c;57(3):241\u20139.","journal-title":"Radiat Environ Biophys"},{"key":"738_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca V, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7\u201318.","journal-title":"Eur J Cancer"},{"issue":"4","key":"738_CR37","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/cancers6042049","volume":"6","author":"OL George","year":"2014","unstructured":"George OL, Ness SA. Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis. Cancers (Basel). 2014;6(4):2049\u201371.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"738_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41590-018-0311-z","volume":"20","author":"S Gautam","year":"2019","unstructured":"Gautam S, et al. The transcription factor c-Myb regulates CD8(+) T cell stemness and antitumor immunity. Nat Immunol. 2019;20(3):337\u201349.","journal-title":"Nat Immunol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00738-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-020-00738-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00738-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T12:05:19Z","timestamp":1604145919000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-020-00738-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1186\/s12894-020-00738-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.01.20115345","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The case study participant provided written consent covering tissue research as part of a prospective tissue collection study for prostate radiobiology research approved by the Human Research Ethics Committee at the Peter MacCallum Cancer Centre (PMCC; HREC approvals 10\/68, 13\/167, 19\/32).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The case study participant provided written consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}